08:54 AM EDT, 09/15/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday it was awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury by the US Department of Defense.

The award will support a three-year study of intranasal anti-CD3 in the acute phase of spinal cord injury, targeting patients who present to the hospital immediately following injury, the company said.

Foralumab, Tiziana's lead development candidate, is a fully human anti-CD3 monoclonal antibody that has been shown to stimulate T regulatory cells when dosed intranasally, the company said.

Tiziana's shares were up more than 9% in recent premarket activity.